Skip to main content

Long-term low dose glucocorticoid therapy in rheumatoid arthritis: a systematic review with meta-analysis on cardiovascular effects

Journal
Clinical and experimental rheumatology (Q2)
Published
7 July 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Emanuele Gotelli, Rosanna Campitiello, Elvis Hysa, Stefano Soldano, Carmen Pizzorni, Sabrina Paolino, et al.
PMID
42454469
DOI
10.55563/clinexprheumatol/omk0if

Why clinicians should know about it

  • Picked for Epidemiology (top studies of the week, 19 July 2026).
  • Picked for Immunology and Allergy (top studies of the week, 19 July 2026).
  • Picked for Rheumatology (top studies of the week, 19 July 2026): Systematic review of low‑dose glucocorticoid cardiovascular effects in RA

Abstract

OBJECTIVES: Glucocorticoids (GCs) are widely used as first-line therapy in rheumatoid arthritis (RA) due to their rapid onset of action and strong efficacy. However, inappropriate use is associated with significant adverse effects. Long-term treatment with low doses has been considered relatively safe for most RA patients, although its cardiovascular (CV) impact remains controversial. METHODS: A systematic literature review was conducted using PubMed to evaluate the CV effects of long-term (≥12 months) low-dose GC therapy (<7.5 mg/day prednisone equivalent) in RA patients. Studies published between 2010 and 15 March 2026 were screened independently by two reviewers. Study quality was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias 2 tool for randomised controlled trials. A meta-analysis was performed to estimate pooled hazard ratios (HRs) with 95% confidence intervals. RESULTS: Ten studies were included in the review, of which five provided adjusted HRs suitable for meta-analysis. Long-term GC exposure even to low doses was associated with an increased risk of CV events (pooled HR 1.37; 95%CI 1.03-1.81; p=0.01). Substantial heterogeneity was observed among studies. Egger's test did not indicate significant publication bias. CONCLUSIONS: Current evidence suggests that while short-term low-dose GC therapy may be relatively safe in selected RA patients, prolonged use and higher cumulative doses are associated with a slight increased CV risk, particularly in individuals with existing risk factors or comorbidities.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.